Soufeng Sanjie Formula Alleviates Collagen-induced Arthritis in Mice by Inhibiting Th17 Cell Differentiation

Di Hua  
Nanjing University of Chinese Medicine

Jie Yang  
Jiangsu Province Academy of Traditional Chinese Medicine

Qinghai Meng  
Nanjing University of Chinese Medicine

Yuanyuan Ling  
Nanjing University of Chinese Medicine

Qin Wei  
Nanjing University of Chinese Medicine

Zhigang Wang  
Jiangsu Province Academy of Traditional Chinese Medicine

Qingyun Wei  
Jiangsu Province Academy of Traditional Chinese Medicine

Jiao Chen  
Jiangsu Province Academy of Traditional Chinese Medicine

Juan Ye  
Jiangsu Province Academy of Traditional Chinese Medicine

Xuan Han  
Nanjing University of Chinese Medicine

Kelei Su  
Jiangsu Province Academy of Traditional Chinese Medicine

Weikang Kong  
Nanjing Medical University

Chao Xu  
Jiangsu Province Academy of Traditional Chinese Medicine

Peng Cao  
Nanjing University of Chinese Medicine

Chunping Hu (njhcp66@126.com)  
Jiangsu Province Academy of Traditional Chinese Medicine
Abstract

Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease. Soufeng sanjie formula (SF), which is composed of scolopendra (dried body of *Scolopendra subspinipes mutilans* L. Koch), scorpion (dried body of *Buthus martensii* Karsch), astragali radix (dried root of *Astragalus membranaceus* (Fisch.) Bge), and black soybean seed coats (seed coats of *Glycine max* (L.) Merr), and is a traditional Chinese prescription for treating RA. However, the mechanism of SF in treating RA remain unclear. This study was aim to investigate the anti-arthritic effects of SF in a collagen-induced arthritis (CIA) mouse model and explore the mechanism by which SF alleviates arthritis in CIA mice.

Methods: For *in vivo* studies, female DBA/1J mice were used to establish the CIA model, and either SF (183 or 550 mg/kg/d) or methotrexate (MTX, 920 mg/kg, twice/week) was orally administered to the mice from the day of arthritis onset. After administration for 30 d, degree of ankle joint inflammatory infiltration and serum levels of IgG and inflammatory cytokines were determined. The balance of Th17/Treg cells in the spleen and lymph nodes was analyzed using flow cytometry. Furthermore, the effect of SF on Th17 cells differentiation *in vitro* was investigated in Th17 polarization.

Results: SF decreased the arthritis score, ameliorated paw swelling, and reduced synovial hyperplasia in the joints of CIA mice. In addition, SF decreased the levels of bovine collagen-specific IgG and inflammatory cytokines (TNF-α, IL-6, and IL-17A) and increased the level of IL-10 in the sera of CIA mice. Moreover, SF treatment rebalanced the Th17/Treg ratio in the spleen and lymph nodes of CIA mice. *In vitro*, SF treatment reduced Th17 cell generation and IL-17A production and inhibited the expression of RORγt, IRF4, and Il-17A under Th17 polarization conditions.

Conclusions: Our results suggest that SF exhibits anti-arthritic effects and restores Th17/Treg homeostasis in CIA mice by inhibiting Th17 cell differentiation.

Background

Rheumatoid arthritis (RA) is a chronic autoimmune disease in which multiple immune cell types and signaling networks malfunction to elicit a maladaptive tissue repair process that leads to organ damage, predominantly in the joints [1]. The most prominent feature of RA is swelling and deformation of the hands, wrists, feet, and knees [2]. RA may occur at any age, and the cumulative lifetime risk of developing adult-onset RA has been estimated at roughly 3.6% for women and 1.7% for men, with a peak incidence age of 50 to 60 years [3].

Substantial evidence has emerged supporting a role for immune cells, including T cells, macrophages, and fibroblasts, as well as inflammatory cytokines, in the initiation and progression of RA [4,5]. CD4+ T helper (Th) cells regulate immunity and inflammation through antigen-dependent activation and cytokine-dependent differentiation into functionally distinct effector and regulatory T cell subsets. The proinflammatory cytokine tumor necrosis factor-α (TNF-α) regulates Treg cells through Foxp3 dephosphorylation, and interleukin-6 (IL-6) and TNF-α trigger naive CD4+ T cell differentiation into Th17
cells [6,7]. However, the imbalance of regulatory T cells (Tregs) and Th17 cells can cause autoimmune diseases [8]. Th17 cells have been shown to stimulate fibroblast-like synoviocytes via interleukin-17 (IL-17) to secrete the cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) and expand synovial-resident innate lymphoid cells in inflamed joints [9]. Therefore, the inhibition of Th17 cell activity and IL-17 expression has become a potential therapeutic target for the treatment of RA.

The current drugs for the treatment of RA are mainly conventional synthetic agents (e.g., methotrexate) and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs) [10]. Several biological DMARDs, including TNF-α blockers and IL-6 receptor (IL-6R) inhibitors, have been used to treat RA [11]. However, most of these drugs act slowly or produce severe adverse reactions after long-term application. Many RA patients do not respond favorably to methotrexate, and not all RA patients respond to biological DMARDs in terms of retardation of joint destruction [12,13]. Therefore, a natural drug formula with good curative effect and low adverse reactions is needed for RA patient.

Traditional Chinese medicine has a significant effect on treating long-term chronic diseases such as RA [14]. SF is composed of scolopendra (dried body of *Scolopendra subspinipes mutilans* L. Koch), scorpion (dried body of *Buthus martensii* Karsch), astragali radix (dried root of *Astragalus membranaceus* (Fisch.) Bge), and black soybean seed coats (seed coats of *Glycine max* (L.) Merr), which is a traditional Chinese medicine for treating RA [15]. All four of its components have been extensively studied, and several studies have shown that some of the components in SF can treat RA. For example, a mixture of scolopendra and scorpion powder can attenuate inflammation and articular damage by normalizing T lymphocyte subsets and the balance of Th1/Th2 cytokines [16]. Astragalus alleviated arthritis in rats by regulating the OPG/RANKL/NF-κB pathway [17]. Black soybean seed coats alleviated arthritis in CIA mice by suppressing nuclear factor kappa-B (NF-κB) signaling [18]. Although SF is a traditional prescription for the treatment of RA and show beneficial clinical effects, only limited studies have been conducted on the pharmacological research of SF to date and the mechanism of SF in treating RA is still unclear [19,15]. In the present study, we investigated the therapeutic potency of SF in a CIA mouse model and explored the possible mechanism of SF in RA treatment via *in vivo* and *in vitro* experiments.

**Methods**

**Reagents**

Processed scorpion (Batch No. 20100108), scolopendra (Batch No. 20200301), astragali radix (Batch No. 2010012), black soybean seed coats (Batch No. 200414), and methotrexate (MTX) were purchased from Jiangsu Integrated Traditional Chinese and Western Medicine Hospital (Nanjing, Jiangsu, China). Calycosin and protocatechuic acid were purchased from Yuanye Bio-Technology (Shanghai, China). Bovine type II collagen and Freund’s adjuvant were purchased from Chondrex (Redmond, WA, USA). An enzyme-linked immunosorbent assay (ELISA) kit for anti-bovine collagen II-specific antibodies was purchased from Chondrex (Redmond, WA, USA). Cell counting kit-8 was purchased from MCE (NJ, USA). Antibodies against interleukin-17 (IL-17) were purchased from Abcam (Cambridge, UK). ELISA kits for
TNF-α, IL-6, IL-17A, and interleukin-10 (IL-10) were purchased from R&D Systems (Minneapolis, MN, USA). Antibodies against anti-mouse CD3, anti-CD4, anti-CD25, anti-Foxp3, and anti-IL-17A were purchased from BD Biosciences (Franklin Lakes, NJ, USA). Anti-mouse CD4 magnetic particles were purchased from BD Biosciences (Franklin Lakes, NJ, USA). The permeabilization solution kit was purchased from BD Biosciences (Franklin Lakes, NJ, USA). The cell stimulation cocktail was purchased from Invitrogen (Carlsbad, CA, USA). The HiScript Reverse Transcription system was purchased from Vazyme Biotech (Nanjing, Jiangsu, China). TRIzol reagent was purchased from Invitrogen (Carlsbad, CA, USA).

**Preparation of SF**

SF was provided by the Pharmacy of Jiangsu Province Hospital on Integration of Chinese and Western Medicine (Jiangsu, China) and was composed of scolopendra, scorpion, astragali radix and black soybean seed coats. The daily dose of SF crude drug administered by humans in the clinic was 0.85 g/kg. The processed scorpion and scolopendra were crushed through an 80-mesh sieve to form a fine powder, which was further crushed into ultrafine powder using a cryogenic ball mill. Astragali radix and black soybean seed coats were decocted twice with 600 mL of water at 100 °C for 1 h to obtain an aqueous extract, based on a previously reported procedure [20]. The aqueous extract was freeze-dried at -80 °C for 72 h to obtain a freeze-dried powder. The freeze-dried SF powder was dissolved in double distilled water and used in the *in vivo* and *in vitro* experiments.

**HPLC-Q-TOF-MS analysis and quality control of SF**

HPLC-Q-TOF-MS analysis was performed to identify the main compounds in SF (50 mg/mL). Chromatographic separation was performed using an Agilent C18 column (3.0 mm × 100 mm, 2.7 μm; Agilent Technologies, Santa Clara, CA, USA) at 40 °C. The mobile phase consisted of water containing 0.1% phosphoric acid (A) and acetonitrile (B). The gradient program was set as follows: 0–0.01 min, 5% B; 0.01–25 min, 5–95% B; 25–27 min, 5% B; 27–30 min, 5% B. The mobile phase flow rate was 0.3 mL/min, and the sample injection volume was 2 μL. Electrospray ionization (ESI) with positive ion modes was used for mass detection. The source parameters were set as follows: spray voltage, 4.5 kV; gas temperature, 550 °C; pressure of nebulizer gas, 55 psi; full scan range, m/z 50–1000.

The main ingredient in SF (50 mg/mL) was confirmed using an Agilent 1260 liquid chromatography system. Methanol (80%) was used as the extraction solvent for the ultrasonic treatment of SF. The SF was separated on an X-Bridge C18 column (250 mm × 4.6 mm, 5 μm) maintained at 25 °C. The mobile phase consisted of acetonitrile (A) and 0.1% phosphate buffer (B) in a gradient elution: 0–10 min, 5% A; 10–11 min, 5–15% A; 11–20 min, 15–18% A; 20–30 min, 18–20% A; 31–40 min, 20–30% A; 31–40 min, 30–37% A; 40–46 min, 37–90% A. The flow rate was 1 mL/min, the injection volume was 10 μL, and detection was set at 260 nm. Chromatographic data were acquired and analyzed using the Empower software (Agilent). The peaks of protocatechuic acid and calycosin in SF were identified by comparing peak retention times with those of the reference compounds.

**Animals**
Six-to-eight-week-old female C57BL/6 and DBA/1J mice were purchased from Changzhou Cavens Experimental Animal Co., Ltd. (Jiangsu, China) and maintained under specific pathogen-free conditions at the Animal Center of Jiangsu Province Academy of Traditional Chinese Medicine. All mice raised in circumstances that alternated between 12 h of light and 12 h of darkness at the temperature of 20–25 °C and relative humidity of 50%–70%. All animal experimental procedures were performed in accordance with the national and international guidelines and regulations, and were approved by the Animal Ethics Committee of Jiangsu Province Academy of Traditional Chinese Medicine.

**CIA induction and drug administration**

CIA mice were immunized twice using bovine type II collagen. In the first immunization, bovine collagen II and Freund's complete adjuvant were mixed and administered as an intradermal injection at the base of the tail in each mouse (100 μg/mouse). On day 21, a booster injection was given using bovine collagen II and Freund’s incomplete adjuvant. DBA/1J female mice were randomly divided into five groups: normal group (Normal, n=5), CIA vehicle group (CIA vehicle, n=5), methotrexate group (MTX, n=5), SF low-dose group (SF-L, 183 mg/kg, n=5), and SF high-dose group (SF-H, 550 mg/kg, n=5). The doses of SF and MTX used in this study were determined from the recommended dosages for humans. SF low-dose was calculated based on a person's daily administration of 1 g of scorpion and scolopendra, and SF high-dose was calculated based on a person's daily administration of 3 g of scorpion and scolopendra. Oral administration of SF (183 or 550 mg/kg/d) began 28 d after the first immunization, and MTX was administered at a dose of 920 mg/kg twice a week. Mice in the normal and vehicle groups were administered an equal volume of deionized water at the same time points.

**Evaluation of arthritis**

The incidence of arthritis was evaluated every 3–4 d following immunization. The severity of arthritis was assessed on a scale of 0–4, based on the following previously described criteria [21]: 0 = no evidence of erythema or swelling; 1 = erythema and mild swelling extending to the tarsals or ankle joint; 2 = erythema and mild swelling extending from the ankle to the tarsals; 3 = erythema and moderate swelling extending from the ankle to metatarsal joints; 4 = erythema and severe swelling encompassing the ankle, foot, and digits, or ankylosis of the limb. The arthritis score for each mouse was expressed as the sum of the scores of all four limbs. The highest arthritis score that a mouse could have was 16. Hind paw swelling was measured using a paw volume meter (Woodland Hills, CA, USA).

**Histological evaluation**

The mice were sacrificed after 30 d of SF treatment and the hind limbs (including paws and ankles) were collected. The hind limbs were fixed in 4% paraformaldehyde solution, which was then decalcified with 10% EDTA for 1 month. After that, the hind limbs were paraffin-embedded, and tissues sectioned and stained with hematoxylin and eosin (H&E). The degree of histopathological damage was evaluated based on previously described criteria [22].
Measurement of cytokine and bovine collagen-specific IgG levels

Blood was collected from each mouse on day 30 of treatment and clotted at 25 °C for 1 h. Blood was centrifuged at 4000 rpm for 15 min to obtain serum, which was then stored at -80 °C until use. The levels of cytokines and bovine collagen-specific IgG were measured using ELISA kits according to the manufacturers’ instructions.

Immunohistochemistry

The hind limb tissue sections were incubated with an anti-IL-17 antibody. After incubation with HRP-conjugated goat anti-rabbit IgG antibody, the expression of IL-17 was visualized using a DAB kit (Servicebio, Wuhan, China). The quantitative analysis of IL-17 in hind limb sections was performed using Image J 1.37v. The results are expressed as the mean region of interest, and the average optical density was used for statistical analysis.

T-cell isolation and cell viability assay

CD4⁺ T cells were isolated from the splenocytes of six-to-eight-week-old female C57BL/6 mice using anti-mouse CD4 magnetic particles and an IMag Cell Separation Magnet. To evaluate the effect of SF on the viability of CD4⁺ T cells, the cells were treated with different concentrations of SF (0.1–1 mg/mL) for 72 h, and cell viability was detected with a cell counting kit-8.

In vitro Th17 cell differentiation

The polarization of Th17 cells was performed as previously described [23], CD4⁺ T cells were stimulated with plate-bound anti-CD3 (1 µg/mL), anti-CD28 (1 µg/mL), anti-interleukin-4 (2 µg/mL), 2 µg/mL anti-interferon-γ (IFN-γ), 2 ng/mL transforming growth factor-β (TGF-β), 30 ng/mL IL-6, 20 ng/mL interleukin-23 (IL-23), and 10 ng/mL interleukin-1β (IL-1β) for 72 h. After 3 d, the cells were re-stimulated with a cell stimulation cocktail and then stained with anti-mouse CD4 and anti-IL-17A antibodies. The level of IL-17A in the cell supernatant was detected using an ELISA kit.

Flow cytometry

After oral administration of SF for 30 d, all mice were sacrificed, and the spleen and lymph nodes extracted, mashed and washed with phosphate-buffered saline (PBS). For intracellular IL-17A and Foxp3 staining, the splenocytes and lymph node cells were stimulated with a leukocyte activation cocktail for 5 h. Next, cells were stained with surface FITC-conjugated anti-CD4 antibody or stained with FITC-conjugated anti-CD4 and APC-conjugated anti-CD25 antibodies. After fixation and permeabilization, cells were stained with PE−conjugated anti−Foxp3 or PE−conjugated anti-IL-17A antibodies. Finally, the cells were analyzed via flow cytometry (BD Biosciences, Franklin Lakes, NJ, USA). Flow Jo v10 was used to further analyze the levels of Treg and Th17 cells.

RNA extraction and real-time qPCR
CD4\(^+\) T cells were cultured for 3 d with or without SF (0.1, 0.5, and 1 mg/mL) under Th17-polarizing conditions. Total RNA was extracted from CD4\(^+\) T cells using TRIzol reagent according to the manufacturer’s protocol. cDNA was synthesized using the HiScript Reverse Transcription system. A 7500 real-time PCR system (Applied Biosystems, Waltham, MA, USA) was used for PCR amplification. All reactions were performed using the ChamQ Universal SYBR qPCR Master Green kit (Vazyme Biotech, Nanjing, China). The \(2^{-\Delta\Delta Ct}\) method was used for data analysis. The primer sequences used are listed in Table 1.

Table 1. Primers used for real-time qPCR in the present study.

| Gene        | Forward                      | Reverse                                    |
|-------------|------------------------------|--------------------------------------------|
| Mouse ROR\(\gamma\) | 5'-GACCCACACCTCACAAATTGA-3'  | 5'-AGTAGGCCACATTACACTGCT-3'               |
| Mouse IL-17A  | 5'-TTTTAECTCCTGGCAGCAAAA-3'  | 5'-CTTTCCCTCCGCGATGGACAC-3'               |
| Mouse IRF4    | 5'-TCCGACAGTGGGATCGAC-3'     | 5'-CCTCACGATTGTAGTCTCCTGCT-3'             |
| Mouse GAPDH   | 5'-TGTGGATGGCCCTCTGGAA-3'    | 5'-TGACCTTGCCACAGCCTTG-3'                 |

**Statistical analysis**

GraphPad Prism (GraphPad Software version 7.0, San Diego, CA, USA) was used for statistical analysis. Data are expressed as the mean ± SEM. One-way ANOVA with Dunnett’s post-hoc multiple comparison tests and two-way ANOVA with Bonferroni post-tests were used to determine statistical significance. Statistical significance was established at \(P<0.05\).

**Results**

**Identification of chemical compounds in SF by HPLC-Q-TOF-MS and quality control of SF**

In the HPLC-Q-TOF-MS experiment, 13 compounds were detected in the SF, as shown in Figure 1A and Table 2. The 13 compounds were tentatively characterized based on their formula and retention times. According to the Chinese Pharmacopoeia, protocatechuic acid and calycosin were used as references to verify the composition of SF. The representative HPLC chromatograms of standards and SF are shown in Fig. 1B and 1C. The content of protocatechuic acid and calycosin in SF were analyzed and generated regression equations using the peak area and concentrations. The content of protocatechuic acid in SF was 0.553 mg/mL. The content of calycosin in SF was 0.291 mg/mL.

**SF suppressed the development of arthritis in CIA mice**

DBA/1J mice were immunized with bovine collagen II twice, and SF was administered orally every day, starting 28 d after the first immunization (Fig. 2A). Mice began to show symptoms of arthritis
28 d following the first immunization. As shown in Fig. 2B, the incidence of arthritis reached 100% 38, 42, 44, and 45 d after immunization in the CIA vehicle group, the MTX group, the SF low-dose group, and the SF high-dose group, respectively. Arthritis scores were assessed and swelling of the hind paw was measured after the booster immunization. Compared with mice in the CIA vehicle group, the arthritis scores of mice in the SF low-dose and SF high-dose groups were significantly reduced from the days 37 to 58 following the first immunization (Fig. 2C). And the arthritis scores of mice in the MTX group was also significantly reduced from the days 34 to 51. Moreover, compared with mice in the CIA vehicle group, the hind paw swelling of mice in the SF (low-dose and high-dose) and MTX groups decreased significantly after day 37 of immunization (Fig. 2D). After administration of SF for 30 d, the hind paw of mice in the CIA vehicle group were severely swollen and deformed, whereas no significant deformation was found among the SF (low-dose and high-dose) and MTX groups (Fig. 2E). Additionally, the body weights of mice in the SF low-dose and SF high-dose groups on days 51, 55 and 58 after immunization were significantly higher than those of the CIA vehicle group mice (Fig. 2F).

**SF reduced ankle joint inflammatory infiltration, serum levels of IgG and inflammatory Cytokines, and ankle joint IL-17A expression**

H&E staining of mice ankle joints revealed a large degree of inflammatory cell infiltration and synovial hyperplasia in the CIA mice, while inflammatory infiltration and synovial hyperplasia in the joints of SF-treated mice were significantly attenuated compared to those of CIA mice (Fig. 3A). The joint histopathological scores of mice in the SF low-dose and SF high-dose groups were also significantly lower than those in the CIA vehicle group (Fig. 3A). Moreover, the levels of bovine collagen II-specific IgG and IgG2a in the sera of mice in the SF low-dose and SF high-dose groups were also significantly lower than those in the CIA vehicle group (Fig. 3B). However, the levels of IgG2b in the sera of mice in the SF low-dose group were lower than those in the CIA vehicle group and the levels of IgG2a in the sera of mice in the MTX group were lower than those in the CIA vehicle group (Fig. 3B). Furthermore, the sera levels of inflammatory cytokines TNF-α, IL-6, and IL-17A were significantly decreased in the SF low-dose and SF high-dose groups compared to those in the CIA vehicle group (Fig. 3C). Meanwhile, the levels of IL-6 and IL-17A were significantly decreased in the MTX group compared to those in the CIA vehicle group (Fig. 3C). And the levels of IL-10 in the sera of mice in the SF high-dose group were higher than those in the CIA vehicle group (Fig. 3C). In addition, the expression levels of IL-17A were significantly downregulated in the ankle joints of the SF (low-dose and high-dose) and MTX groups compared with those in the CIA vehicle group (Fig. 3D).

**SF treatment rebalanced Th17/Treg ratio in the spleen and lymph nodes of CIA mice**

As shown in the above results, the sera levels of TNF-α, IL-6, and IL-17A and the expression of IL-17 in the joints of the SF treatment groups were significantly lower than those in the CIA group, while sera IL-10 levels were significantly increased. We next investigated the effect of SF on the immune balance in CIA mice. After administration of SF for 30 d, we measured the numbers of Treg and Th17 cells in the spleen
and lymph nodes of the mice. As shown in Fig. 4 and Fig. 5, compared to the normal mice, the number of Th17 (CD4⁺IL-17⁺) cells was significantly increased in the spleen and lymph nodes of CIA mice, while the number of Treg (CD4⁺CD25⁺Foxp3⁺) cells was significantly decreased in the spleen of CIA mice. Meanwhile, the ratio of Th17/Treg cells in the spleen and lymph nodes of the CIA vehicle group was significantly higher than that in the normal group (Fig. 4 and Fig. 5). However, compared with mice in the CIA vehicle group, the numbers of Th17 cells and the ratio of Th17/Treg in the spleen and lymph nodes of the SF (low-dose and high-dose) and MTX groups were significantly reduced (Fig. 4 and Fig. 5). Note that only the number of Treg cells in the spleen of mice in the SF high-dose group increased significantly and the number of Th17 cells in the lymph nodes of mice in the MTX group decreased significantly (Fig. 4 and Fig. 5).

**SF inhibited Th17 cell differentiation and Th17-related mRNA expression in vitro**

Next, we investigated the effect of SF on Th17 cells using an *in vitro* model of Th17 cell differentiation. First of all, CD4⁺ T cells were isolated from the splenocytes of C57BL/6 mice and treated with different concentrations of SF (0.1–1 mg/mL). As shown in Figure 6A, SF (0.1-1 mg/mL) had no effect on CD4⁺ T cell viability. The CD4⁺ T cells were then incubated under Th17-polarizing conditions in the presence or absence of SF (0.1–1 mg/mL). SF reduced IL-17A levels in the cell supernatant in a dose-dependent manner (Fig. 6B). Moreover, compared with unpolarized CD4⁺ T cells, the number of Th17 cells increased significantly after polarization, while Th17 cells in the SF treatment group decreased significantly in a dose-dependent manner (Fig. 6C and 6D). Next, the mRNA expression of Th17-associated cytokines and Th17-specific transcription cytokine RORγt were analyzed. Compared with unpolarized CD4⁺ T cells, the mRNA levels of IL-17A, RORγt, and IRF4 in CD4⁺ T cells under Th17 polarization conditions increased significantly, while the mRNA levels of IL-17A and RORγt in the SF treatment group decreased significantly in a dose-dependent manner (Fig. 6E). However, only SF 1 mg/ml significantly reduced the mRNA level of IRF4 (Fig. 6E).

Table 2. Characteristics of compounds identified in SF through HPLC-Q-TOF-MS
| NO | Rt (min) | Identification                                                                 | Formula        | m/z             | Error (ppm) |
|----|---------|-------------------------------------------------------------------------------|----------------|-----------------|-------------|
| 1  | 0.66    | L(+)-Arginine                                                                | C$_6$H$_{14}$N$_4$O$_2$ | [M+H]$^+$       | -0.6        |
|    |         |                                                                               |                | 175.1189        |             |
| 2  | 0.72    | L-Proline                                                                     | C$_5$H$_9$NO$_2$ | [M+H]$^+$       | -0.5        |
|    |         |                                                                               |                | 116.0706        |             |
| 3  | 3.22    | 2-(7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10-yl)acetaldehyde                  | C$_{14}$H$_{12}$N$_4$O$_3$ | [M+NA]$^+$     | 4.7         |
|    |         |                                                                               |                | 307.0801        |             |
| 4  | 4.08    | Epicatechin                                                                   | C$_{15}$H$_{14}$O$_6$ | [M+H]$^+$       | 2           |
|    |         |                                                                               |                | 291.0863        |             |
| 5  | 6.71    | L-Leucine                                                                     | C$_6$H$_{13}$NO$_2$ | [M+COOH]$^+$   | 2           |
|    |         |                                                                               |                | 176.0917        |             |
| 6  | 8.11    | Calycosin                                                                     | C$_{16}$H$_{32}$O$_5$ | [M+H]$^+$       | 0.8         |
|    |         |                                                                               |                | 285.0757        |             |
| 7  | 8.57    | Fmoc-L-1,2,3,4-tetrahydro-norharman-3-carboxylic acid                         | C$_{27}$H$_{22}$N$_2$O$_4$ | [M+H]$^+$     | -5          |
|    |         |                                                                               |                | 439.1652        |             |
| 8  | 11.57   | Palmitic acid                                                                 | C$_{16}$H$_{32}$O$_2$ | [M+NH$_2$]$^+$ | 3.1         |
|    |         |                                                                               |                | 272.2584        |             |
| 9  | 11.83   | Oleic acid                                                                    | C$_{18}$H$_{34}$O$_2$ | [M+NH$_2$]$^+$ | 0.4         |
|    |         |                                                                               |                | 298.2740        |             |
| 10 | 12.84   | Ethyl 3,4-dihydroxybenzoate                                                  | C$_9$H$_{10}$O$_4$ | [M+H]$^+$       | 1.9         |
|    |         |                                                                               |                | 183.0651        |             |
| 11 | 13.73   | Astragaloside I                                                               | C$_{45}$H$_{72}$O$_{16}$ | [M+COOH]$^+$ | 3.2         |
|    |         |                                                                               |                | 913.4791        |             |
| 12 | 14.39   | Delphinidin chloride                                                          | C$_{15}$H$_{11}$ClO$_7$ | [M+COOH]$^+$ | 0.8         |
|    |         |                                                                               |                | 383.0164        |             |
| 13 | 15.39   | α-Linolenic acid                                                              | C$_{18}$H$_{32}$O$_2$ | [M+H]$^+$       | 1.7         |
|    |         |                                                                               |                | 279.2318        |             |
Discussion

Previous studies have shown that traditional Chinese medicine is an alternative medicine for treating long-term chronic diseases such as RA [24]. Traditional Chinese medicine, characterized by monarch, minister, adjuvant and assistant emphasizes the integrated treatment based on multicomponent action instead of the single-component therapy, which is the typical superiority of traditional Chinese medicine prescription. Treatment by the combination formulae has been verified scientifically for treatment on several diseases as an effective complementary or alternative therapy [25]. In the present study, we demonstrated that SF had a significant therapeutic effect in a CIA mouse model, as evidenced by significantly decreased arthritis scores, joint swelling, and synovial hyperplasia in CIA mice treated with SF compared with CIA vehicle mice. This beneficial effect of SF may be through maintaining the balance of Treg/Th17 cells, down-regulating the expression of TNF-α, IL-6, IL-17A, up-regulating IL-10 expression, and inhibiting the formation of IgG antibodies.

The pathogenesis of RA is complex, TNF-α and IL-6 are considered to be central hubs in the synovial cytokine network of RA [26]. These cytokines stimulate osteoclast formation and the subsequent degradation of bone and cartilage, and also potently induce the release of other pro-inflammatory mediators, such as IL-1 and granulocyte-macrophage colony-stimulating factor [27]. In the present study, we found that SF significantly decreased the levels of TNF-α, IL-6, and IL-17A in the sera of CIA mice, while sera IL-10 levels were significantly increased. IL-6 mediates Th17 differentiation, and Th17 cells produce inflammatory cytokines, such as IL-17, to augment autoimmune arthritis [9,28]. Moreover, anti-inflammatory interleukin-10 (IL-10) endows Treg cells with the ability to suppress pathogenic Th17 cell responses [29]. We also found that the expression of IL-17 in the joints of CIA mice after SF treatment was significantly downregulated. Based on these results, we investigated the effect of SF on Treg and Th17 cells in the spleen and lymph nodes of CIA mice.

CD4+ T helper (Th) cells play central roles in RA regulation [30]. Naive precursor CD4+ T cells develop into Th17 cells when exposed to proinflammatory cytokines, including TGF-β, IL-6, IL-1β, and IL-23 [31], and the pro-inflammatory cytokines produced by Th17 cells are involved in the development of RA [32]. In contrast to Th17 cells, Tregs are indispensable mediators that sustain immune tolerance to self-antigens and help to maintain immune homeostasis [33]. In the present study, although only SF high-dose significantly increased the number of Treg cells in the spleen of CIA mice, SF had a significant inhibitory effect on Th17 cells in the spleen and lymph nodes of CIA mice. Furthermore, the ratio of Th17/Treg in the spleen and lymph nodes of CIA mice after SF treatment returned levels similar to that in normal mice. Our findings are consistent with those of other studies showing that maintaining the balance between Th17 and Treg cells is essential for the treatment of RA [6,8].

Although IL-17 antibodies show marked clinical efficacy in psoriasis, targeting IL-17 alone is not sufficient to improve clinical end points in other autoimmune conditions, namely RA [34]. Targeting the Th17 cell
lineage may show better anti-RA effects. We found that SF not only significantly decreased the number of Th17 cells in the spleen and lymph nodes of CIA mice, but it could also significantly inhibit the production of Th17 cells 

\textit{in vitro}. RORγt is a key transcription factor that controls the differentiation of Th17 cells and induces the expression of genes encoding IL-17 and IL-17F cytokines [35]. IL-6 can induce the upregulation of RORγt expression, initiating the RORγt signal transduction pathway to promote Th17 cell differentiation [36]. Our results showed that SF can significantly decrease the level of IL-6 in the sera of CIA mice and that SF can significantly suppress the expression of RORγt. Furthermore, the expression of interferon-regulatory cytokine 4 (IRF4) was also suppressed by SF. IRF4 is essential for the development of Th17 cells and mainly regulates the secretion of IL-17 and IL-21 [37]. These results suggest that SF may inhibit the differentiation of Th17 cells by suppressing the expression of RORγt and IRF4.

This study confirmed, for the first time, that SF could maintain immune balance by inhibiting Th17 cell differentiation, which indicates that SF is an alternative drug candidate for the treatment of RA. However, more research should be conducted to clarify the mechanism by which SF inhibits Th17 cell differentiation. In addition, osteoclasts play a major role in joint destruction, which is the main cause of functional damage in patients with RA [38]. Whether there exists a regulatory mechanism by which SF inhibits the formation of osteoclasts and slows down the development of bone erosion needs further investigation.

**Conclusion**

In conclusion, our results suggest that SF exhibits anti-arthritic effects and restores Th17/Treg homeostasis in CIA mice by inhibiting Th17 cell differentiation.

**Abbreviations**

RA, rheumatoid arthritis; CIA, collagen-induced arthritis; SF, soufeng sanjie formula; MTX, methotrexate; HPLC, high performance liquid chromatography; HPLC-Q-TOF-MS, high performance liquid chromatography-quadrupole-time-of-flight mass spectrometry; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; IL-17, interleukin-17; IL-10, interleukin-10; ELISA, enzyme-linked immunosorbent assay; IRF4, interferon regulatory factor 4; RORγt, retinoid-related orphan nuclear receptor γt.

**Declarations**

**Author’s contributions**

Chunping Hu, Peng Cao and Jie Yang designed the study; Di Hua, Yuanyuan Ling, Qin Wei, Xuan Han and Zhigang Wang carried out the experiments; Di Hua, Qingyun Wei, Jiao Chen and Juan Ye performed the data analysis; Weikang Kong, Chao Xu and Kelei Su provided manuscript preparation; Di Hua, Jie Yang and Qinghai Meng wrote and revised the manuscript. All authors read and approved the final manuscript.

**Acknowledgements**
Funding

This study was supported by Jiangsu Academy of Traditional Chinese Medicine (BM2018024-2019003), and the National Natural Science Foundation of China (No. 81773973).

Availability of data and materials

The data used to support the findings of this study are available from the corresponding author upon request.

Ethics approval and consent to participate

All procedures were performed in accordance with the guidelines of the Nanjing University of Chinese Medicine ethics committee.

Consent for publication

Not applicable.

Conflicts of interest

The authors declare no competing interests.

Author details

aAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China. bCollege of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China. cAffiliated Hospital of Yifu, Nanjing Medical University, Nanjing 211166, China

References

1. Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nat Immunol. 2021 Jan;22(1):10–18.

2. Sparks JA. Rheumatoid Arthritis. Ann Intern Med. 2019 Jan 1;170(1):ITC1-ITC16.

3. Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 2014 Aug;35(3):347–69.

4. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007 Jun;7(6):429–42.

5. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011 Dec;8(23):2205–19. 365(
6. Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev. 2014 Jun;13(6):668–77.

7. Nie H, Zheng Y, Li R, Guo TB, He D, Fang L, Liu X, Xiao L, Chen X, Wan B, Chin YE, Zhang JZ. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis. Nat Med. 2013 Mar;19(3):322–8.

8. Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kondoh G, Tanaka A, Yasuda K, Kopf M, Potocnik AJ, Stockinger B, Sakaguchi N, Sakaguchi S. Autoimmune Th17 Cells Induced Synovial Stromal and Innate Lymphoid Cell Secretion of the Cytokine GM-CSF to Initiate and Augment Autoimmune Arthritis. Immunity. 2018 Jun 19;48(6):1220–1232.e5.

9. Hirota K, Hashimoto M, Ito Y, Matsuura M, Ito H, Tanaka M, Watanabe H, Kondoh G, Tanaka A, Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kondoh G, Tanaka A, Yasuda K, Kopf M, Potocnik AJ, Stockinger B, Sakaguchi N, Sakaguchi S. Autoimmune Th17 Cells Induced Synovial Stromal and Innate Lymphoid Cell Secretion of the Cytokine GM-CSF to Initiate and Augment Autoimmune Arthritis. Immunity. 2018 Jun 19;48(6):1220–1232.e5.

10. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, Mclnnnes IB, Solomon DH, Strand V, Yamamoto K. Rheumatoid arthritis. Nat Rev Dis Primers. 2018 Feb 8;4:18001.

11. Kerschbaumer A, Sepriano A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, Mclnnnes IB, Bijlsma JWJ, Burmester GR, de Wit M, Falzon L, Landewé R. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020 Jun;79(6):744–59.

12. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, Müller-Ladner U, Mysler EF, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruyssev-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R van der. Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):685–99.

13. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 Oct 22;388(10055):2023–2038.

14. Lv QW, Zhang W, Shi Q, Zheng WJ, Li X, Chen H, Wu QJ, Jiang WL, Li HB, Gong L, Wei W, Liu H, Liu AJ, Jin HT, Wang JX, Liu XM, Li ZB, Liu B, Shen M, Wang Q, Wu XN, Liang D, Yin YF, Fei YY, Su JM, Zhao LD, Jiang Y, Li J, Tang FL, Zhang FC, Lipsky PE, Zhang X. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial. Ann Rheum Dis. 2015 Jun;74(6):1078–86.

15. Zhong H, Zhao J. Clinical application of insect drugs. J Tradit Chin Med. 2003 Dec;23(4):257–9.

16. Liu DY, Zhao HM, Cheng SM, Rao Y, Huang XY, Zuo ZQ, Lei M, Guan YM, Liu HN, Lu AP. Scorpio and Scolopendra attenuate inflammation and articular damage in rats with collagen-induced arthritis. J
17. Liu XY, Xu L, Wang Y, Li JX, Zhang Y, Zhang C, Wang SS, Zhang XM. Protective effects of total flavonoids of Astragalus against adjuvant-induced arthritis in rats by regulating OPG/RANKL/NF-κB pathway. Int Immunopharmacol. 2017 Mar;44:105–14.

18. Min HK, Kim SM, Baek SY, Woo JW, Park JS, Cho ML, Lee J, Kwok SK, Kim SW, Park SH. Anthocyanin Extracted from Black Soybean Seed Coats Prevents Autoimmune Arthritis by Suppressing the Development of Th17 Cells and Synthesis of Proinflammatory Cytokines by Such Cells, via Inhibition of NF-κB. PLoS One. 2015 Nov 6;10(11):e0138201.

19. Liu XD, Zhang JL, Ye LH. [Effects of wenhua juanbi recipe on TNF-alpha and IL-1beta in peripheral blood of rheumatoid arthritis patients]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2009 Sep;29(9):787–90. Chinese.

20. Zheng H, Qiu F, Zhao H, Chen J, Wang L, Zou H. Simultaneous determination of six bioactive saponins from Rhizoma Panacis Japonici in rat plasma by UHPLC-MS/MS: Application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Aug 15;1092:199–206. doi: 10.1016/j.jchromb.2018.06.016. Epub 2018 Jun 7. PMID: 29908469.

21. Zhou L, Wang J, Li J, Li T, Chen Y, June RR, Zheng SG. 1,25-Dihydroxyvitamin D3 Ameliorates Collagen-Induced Arthritis via Suppression of Th17 Cells Through miR-124 Mediated Inhibition of IL-6 Signaling. Front Immunol. 2019 Feb;7:10:178.

22. Tong T, Park J, Moon Y, Kang W, Park T. α-ionone Protects Against UVB-Induced Photoaging in Human Dermal Fibroblasts. Molecules. 2019 May;9(9):1804. 24(

23. Moon SJ, Park JS, Woo YJ, Lim MA, Kim SM, Lee SY, Kim EK, Lee HJ, Lee WS, Park SH, Jeong JH, Park SH, Kim HY, Cho ML, Min JK. Rebamipide suppresses collagen-induced arthritis through reciprocal regulation of th17/treg cell differentiation and heme oxygenase 1 induction. Arthritis Rheumatol. 2014 Apr;66(4):874–85.

24. Corson TW, Crews CM. Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell. 2007 Sep 7;130(5):769–74.

25. Xue T, Roy R. Studying traditional Chinese medicine. Science. 2003 May 2;300(5620):740-1.

26. Chen Z, Bozec A, Ramming A, Schett G. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat Rev Rheumatol. 2019 Jan;15(1):9–17.

27. Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, Kopf M, Katada Y, Tanaka T, Suemura M, Kishimoto T. Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci U S A. 1998 Jul;7(14):8222–6. 95().

28. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008 Apr;28(4):454–67.

29. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich JM, Jack RS, Wunderlich FT, Brüning JC, Müller W, Rudensky AY. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity. 2011 Apr 22;34(4):566 – 78.
30. Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations (*). Annu Rev Immunol. 2010;28:445–89.

31. Peck A, Mellins ED. Breaking old paradigms: Th17 cells in autoimmune arthritis. Clin Immunol. 2009 Sep;132(3):295–304.

32. Hsu HC, Yang P, Wang J, Wu Q, Myers R, Chen J, Yi J, Guentert T, Tousson A, Stanus AL, Le TV, Lorenz RG, Xu H, Kolls JK, Carter RH, Chaplin DD, Williams RW, Mountz JD. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol. 2008 Feb;9(2):166–75.

33. Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell. 2010 Mar 19;140(6):845–58.

34. Yang J, Sundrud MS, Skepner J, Yamagata T. Targeting Th17 cells in autoimmune diseases. Trends Pharmacol Sci. 2014 Oct;35(10):493–500.

35. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006 Sep 22;126(6):1121–33.

36. Basso AS, Cheroutre H, Mucida D. More stories on Th17 cells. Cell Res. 2009 Apr;19(4):399–411.

37. Staudt V, Bothur E, Klein M, Lingnau K, Reuter S, Grebe N, Gerlitzki B, Hoffmann M, Ulges A, Taube C, Dehzad N, Becker M, Stassen M, Steinborn A, Lohoff M, Schild H, Schmitt E, Bopp T. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity. 2010 Aug;27(2):192–202.

38. Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018 Apr 27;6:15.